Artiva Biotherapeutics has appointed Thad Huston to the position of Chief Financial Officer, leveraging his extensive background in the pharmaceutical, biotechnology, and medical device sectors. Huston brings more than three decades of global leadership experience to the role as the company advances its pipeline toward key regulatory and clinical milestones.
As part of his appointment, Huston received an inducement grant of 220,000 restricted stock units, scheduled to vest over a four-year period. The hiring follows Artiva's strategic positioning ahead of anticipated FDA feedback on its lead candidate AlloNK and planned clinical efficacy data disclosures in rheumatoid arthritis during the first half of 2026.
The CFO appointment reflects Artiva's preparation for an active period of regulatory engagement and clinical development. Huston's appointment comes at a critical juncture as the company navigates key value-inflecting catalysts in its development program.